NextDocs scoops up $5M; Signal Genetics highlights independent study of algorithms for breast cancer prognoses;

> NextDocs, a provider of data management for drug developers, scooped up $5 million in a round of financing after grabbing a $10 million round of growth equity from OpenView Venture Partners two years ago. Item

> Signal Genetics touted results from a Weill Cornell study of its algorithms for providing prognoses for cases of breast cancer. Release

> Here's a case study of Merck's ($MRK) use of an electronic lab notebook from PerkinElmer. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.